The effects of @entity4678 on emotional control in adults with XXXX : An integrated analysis of multicenter studies.

@entity1 @entity71 @entity4678
PURPOSE: To investigate the effects of @entity4678 on emotional control in adults with @entity71 . METHODS: We performed an integrated analysis using individual @entity1 data pooled from three Eli Lilly-sponsored studies. An integrated analysis can be viewed as a meta-analysis of individual @entity1 -level data, rather than study-level summary data. RESULTS: Two populations were identified: a large sample of @entity1 with pre-treatment baseline data (the "overall population"; n=2846); and a subset of these @entity1 with placebo-controlled efficacy data from baseline to 10 or 12weeks after initiating treatment (the "placebo-controlled population"; n=829). At baseline, in the overall population,    50% of @entity71 @entity1 had BRIEF-AS (Behavior Rating Inventory of Executive Function-Adult Version Self-Report) Emotional control subscores between 21 and 30, compared with    10% of normative subjects in the BRIEF-A manual. At endpoint, in the placebo-controlled population, @entity4678 led to a small (effect size 0.19) but significant (P=0.013) treatment effect for emotional control. The effect size was 0.32 in @entity1 with BRIEF-AS Emotional control scores>20 at baseline. Improvements in emotional control correlated with improvements in the core @entity71 symptoms and quality-of-life. DISCUSSION: As deficient emotional control is associated with impaired social, educational and occupational functioning over and above that explained by core @entity71 symptoms alone, improvements in emotional control may be clinically relevant. CONCLUSION: At baseline, adults with @entity71 were more likely to have impaired emotional control than normative subjects. In the adult @entity71 @entity1 , @entity4678 treatment was associated with improvements in emotional control, as well as in core @entity71 symptoms and quality-of-life.
